Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CGEM Stock Forecast 2025-2026
$8.14
Current Price
$476.29M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CGEM Price Targets
+342.3%
To High Target of $36.00
+299.3%
To Median Target of $32.50
+231.7%
To Low Target of $27.00
CGEM Price Momentum
+0.5%
1 Week Change
+1.5%
1 Month Change
-67.8%
1 Year Change
-33.2%
Year-to-Date Change
-73.0%
From 52W High of $30.19
+18.8%
From 52W Low of $6.85
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Cullinan (CGEM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CGEM and similar high-potential opportunities.
Latest CGEM Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, CGEM has a bullish consensus with a median price target of $32.50 (ranging from $27.00 to $36.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $8.14, the median forecast implies a 299.3% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Driscoll at Wedbush, projecting a 342.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CGEM Analyst Ratings
9
Buy
0
Hold
0
Sell
CGEM Price Target Range
Low
$27.00
Average
$32.50
High
$36.00
Current: $8.14
Latest CGEM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CGEM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $33.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $35.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $33.00 |
| Jan 29, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $33.00 |
| Oct 24, 2024 | UBS | David Dai | Buy | Initiates | $30.00 |
| Oct 16, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $28.00 |
| Sep 18, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $36.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $28.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $28.00 |
| Aug 9, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $36.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $28.00 |
| May 24, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $28.00 |
| May 16, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $36.00 |
| May 16, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $28.00 |
| May 1, 2024 | Stifel | Bradley Canino | Buy | Initiates | $40.00 |
| Apr 17, 2024 | BTIG | Kaveri Pohlman | Buy | Maintains | $30.00 |
| Apr 17, 2024 | JonesTrading | Soumit Roy | Buy | Maintains | $26.00 |
| Apr 16, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $29.00 |
| Apr 15, 2024 | William Blair | Matt Phipps | Outperform | Initiates | $0.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $34.00 |
Cullinan Therapeutics Inc. (CGEM) Competitors
The following stocks are similar to Cullinan based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cullinan Therapeutics Inc. (CGEM) Financial Data
Cullinan Therapeutics Inc. has a market capitalization of $476.29M with a P/E ratio of 9.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -32.1%.
Valuation Metrics
Market Cap
$476.29M
Enterprise Value
$79.47M
P/E Ratio
9.0x
PEG Ratio
-2.5x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+83.8%
Current Ratio
13.5x
Debt/Equity
0.4x
ROE
-32.1%
ROA
-22.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cullinan Therapeutics Inc. (CGEM) Business Model
About Cullinan Therapeutics Inc.
What They Do
Develops targeted therapies for cancer treatment.
Business Model
Cullinan Therapeutics Inc. operates as an early-stage biopharmaceutical company, focusing on the development of innovative cancer therapies through immuno-oncology and precision medicine. The company generates revenue by advancing its drug candidates through various stages of clinical trials, ultimately aiming to commercialize successful therapies that address unmet medical needs in oncology.
Additional Information
With a diverse pipeline targeting specific mutations and tumor mechanisms, Cullinan Therapeutics is positioned to contribute significantly to the biotechnology sector. Its strategic emphasis on novel drug development processes enhances its market relevance and potential for growth in the competitive landscape of cancer treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
111
CEO
Mr. Nadim Ahmed
Country
United States
IPO Year
2021
Website
cullinantherapeutics.comCullinan Therapeutics Inc. (CGEM) Latest News & Analysis
Latest News
Quick Summary
Cullinan and Taiho reported that the Phase 2b study successfully met its primary endpoint, achieving the targeted overall response rate.
Why It Matters
Positive Phase 2b results indicate potential for drug efficacy, boosting investor confidence in Cullinan and Taiho's future prospects and possibly increasing stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A company-sponsored clinical trial will begin in Q2 2025 at FAU Erlangen-Nuremberg, Germany, and Università Cattolica del Sacro Cuore, Rome.
Why It Matters
The initiation of a clinical trial in 2025 signals potential advancements in product development, impacting future revenue and market position, which can affect stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2 months ago
Quick Summary
Cullinan Therapeutics expects initial data from its Phase 1 study of CLN-978 for systemic lupus erythematosus in Q4 2025. Cash reserves of $606.9 million provide funding through 2028.
Why It Matters
CLN-978's unique position in SLE trials and upcoming Phase 2b results can drive stock value. Strong cash reserves ensure operational stability through 2028, appealing to long-term investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) will participate in upcoming investor conferences, featuring CEO Nadim Ahmed and Dr. Jeffrey Jones.
Why It Matters
Cullinan Therapeutics' participation in investor conferences signals potential growth opportunities and increased visibility, which can impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
No specific financial information or developments are provided in the excerpt. Therefore, there's nothing relevant for investors to consider from this text.
Why It Matters
Location mentions suggest potential collaborations or economic developments. Investors may anticipate market movements or opportunities in these regions linked to new partnerships or innovations.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cullinan Therapeutics focuses on precision medicine and immunotherapy. Zipalertinib shows a 40% response rate for NSCLC. CGEM's cash reserves may fund operations until 2028, minimizing equity raise needs.
Why It Matters
Cullinan Therapeutics' promising drug trials and strong financial position may lead to future growth, making it an attractive option for investors despite current market challenges.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About CGEM Stock
What is Cullinan Therapeutics Inc.'s (CGEM) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Cullinan Therapeutics Inc. (CGEM) has a median price target of $32.50. The highest price target is $36.00 and the lowest is $27.00.
Is CGEM stock a good investment in 2025?
According to current analyst ratings, CGEM has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CGEM stock?
Wall Street analysts predict CGEM stock could reach $32.50 in the next 12 months. This represents a 299.3% increase from the current price of $8.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cullinan Therapeutics Inc.'s business model?
Cullinan Therapeutics Inc. operates as an early-stage biopharmaceutical company, focusing on the development of innovative cancer therapies through immuno-oncology and precision medicine. The company generates revenue by advancing its drug candidates through various stages of clinical trials, ultimately aiming to commercialize successful therapies that address unmet medical needs in oncology.
What is the highest forecasted price for CGEM Cullinan Therapeutics Inc.?
The highest price target for CGEM is $36.00 from Robert Driscoll at Wedbush, which represents a 342.3% increase from the current price of $8.14.
What is the lowest forecasted price for CGEM Cullinan Therapeutics Inc.?
The lowest price target for CGEM is $27.00 from at , which represents a 231.7% increase from the current price of $8.14.
What is the overall CGEM consensus from analysts for Cullinan Therapeutics Inc.?
The overall analyst consensus for CGEM is bullish. Out of 11 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $32.50.
How accurate are CGEM stock price projections?
Stock price projections, including those for Cullinan Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 12:33 PM UTC